UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

UroGen has issued $4m in ordinary shares to IconOVir. Credit: MacroEcon/Shutterstock. UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic ...

Replimune has established itself as a leader in the field of oncolytic immunotherapy, focusing on developing novel treatments for various cancers. The company's wholly-owned pipeline and advanced ...

(NASDAQ: URGN), a biotech company focused on urothelial and specialty cancers trading at $10.82 per share, has announced the acquisition of a novel oncolytic virus, ICVB-1042, from IconOVir Bio ...

“The acquisition of ICVB-1042, a next-generation investigational oncolytic virus, marks a significant milestone in our plan to develop novel, locally administered therapies for bladder cancer ...

Biotherapeutics announced that Northwestern University/Northwestern Memorial Hospital is starting recruitment for the CLD-101 ...

Replimune has established itself as a leader in the field of oncolytic immunotherapy, focusing on developing novel treatments for various cancers. The company's wholly-owned pipeline and advanced ...

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company focused on urothelial and specialty cancers trading at $10.82 per share, has announced the acquisition of a novel oncolytic virus ...